Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
暂无分享,去创建一个
[1] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[2] Anastasia Khvorova,et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.
[3] K. Kaneko,et al. siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. , 2005, Biochemical and biophysical research communications.
[4] Elena Cattaneo,et al. Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.
[5] I. Kanazawa,et al. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA , 2005, Neuroscience Research.
[6] R. Mandel,et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] S. Batalov,et al. Antisense Transcription in the Mammalian Transcriptome , 2005, Science.
[8] S. Salzberg,et al. The Transcriptional Landscape of the Mammalian Genome , 2005, Science.
[9] Xiaoan Ruan,et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation , 2005, Nucleic acids research.
[10] M. Hayden,et al. Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.
[11] H. Paulson,et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Steer,et al. Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. , 2005, Biochemical and biophysical research communications.
[13] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[14] S. Akira,et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.
[15] B. Cullen,et al. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. , 2005, RNA.
[16] H. Robertson,et al. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington′s disease transgenic mice prior to the onset of motor symptoms , 2004, Neuroscience.
[17] D. Rubinsztein,et al. Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease , 2004, The Journal of Neuroscience.
[18] Aimee L Jackson,et al. Noise amidst the silence: off-target effects of siRNAs? , 2004, Trends in genetics : TIG.
[19] C. Steer,et al. Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation. , 2004, Biochemical and biophysical research communications.
[20] R. Mandel,et al. Clinical trials in neurological disorders using AAV vectors: promises and challenges. , 2004, Current opinion in molecular therapeutics.
[21] John J Rossi,et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.
[22] Xiao-Jiang Li,et al. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.
[23] Ruth Luthi-Carter,et al. Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice , 2003, The Journal of Neuroscience.
[24] Robert H. Silverman,et al. Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.
[25] B. Li,et al. Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.
[26] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[27] S. Hersch,et al. Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease , 2002, The Journal of Neuroscience.
[28] W. Hauswirth,et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.
[29] Ole A. Andreassen,et al. Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.
[30] H. Robertson,et al. Immediate‐early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice , 2002, Journal of neuroscience research.
[31] C. Nellemann,et al. Inhibition of Huntingtin Synthesis by Antisense Oligodeoxynucleotides , 2000, Molecular and Cellular Neuroscience.
[32] L. Thompson,et al. Antisense-mediated down-regulation of the human huntingtin gene. , 2000, The Journal of pharmacology and experimental therapeutics.
[33] Y. Kawaoka,et al. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice , 2000, Nature Medicine.
[34] S. Hersch,et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.
[35] Ole A. Andreassen,et al. Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.
[36] P. Greengard,et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[38] M. Chesselet,et al. Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.
[39] K. Taira,et al. Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme. , 2000, Journal of inorganic biochemistry.
[40] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[41] R. Kalb,et al. Sequence‐specific cleavage of Huntingtin mRNA by catalytic DNA , 1999, Annals of neurology.
[42] B. Byrne,et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.
[43] J. Penney,et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.
[44] C. Ross,et al. Expression of the Huntington's disease (IT15) protein product in HD patients. , 1995, Human molecular genetics.
[45] Christopher A Ross,et al. Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.
[46] G. Hammond,et al. Tissue distribution of alpha 1-proteinase inhibitor messenger ribonucleic acid and its regulation by glucocorticoids in fetal and neonatal sheep. , 1993, Biology of reproduction.
[47] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[48] J. Gauldie,et al. Ontogeny and tissue distribution of alpha-1-antitrypsin of the mouse. , 1981, Biochimica et biophysica acta.